PharmaVOICE - 
October 2002
Purchase Issue

In Every Issue
Talent Pool
Pharma POOL Dr. Jack GOLDSTEIN Chiron Names Blood Testing Division [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES The Rosetta [...]
By
What’s New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES TrialCard’s patented “IA Technology” [...]
By
PharmaTrax
NEUROTHERAPEUTICS AND GENE AMPLIFICATION Markets Predicted to Grow Unmet need [...]
By
For Art’s Sake
CREATIVE review There are many times in healthcare advertising when [...]
By
Pharma Outlet
Fewer new drug approvals, the political spotlight on the pharmaceutical [...]
By

Rico Viray

What’s on your mind: Opinions
R&D will tell I am not sure that the mega [...]
By
Raise Your Voice: Letters
Missed opportunity I applaud the fact that PharmaVOICE has highlighted [...]
By
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh [...]
By

Taren Grom, Editor

On The Cover

Practical Medicine:
Diagnosing the condition DERMAN. Insurance and reimbursement are two big challenges. Part of the problem is that reimbursement rates have dropped, thus physicians need to see more patients, more efficiently, in the same period of time to cover overhead. This is true even in an academic environment. The days of external support for the clinicalpractice [...]
By

Taren Grom, Editor

Features

Dr. Jon Adler — Medicine Man
Man FROM THE EMERGENCY ROOM TO THE BOARDROOM, Jonathan N. Adler, M.D., is committed to the practice of medicine. As a physician, lecturer, and president and chief medical officer of eMedicine, he balances all endeavors with one goal in mind: fostering better medicine. BY KIM RIBBINK JON Adler PharmaVOICE The demands of medicine mean physicians [...]
By

Kim Ribbink

Xyrem: Awakenings
PharmaVOICE approved for treating cataplexy. Of the esti mated 140,000 Americans who suffer from narcolepsy, between 60% and 90% experience cataplexy. Orphan Medical Inc. developed Xyrem under the FDA’s Orphan Drug Act of 1983, which provides market exclusivity to companies that develop products for small, underserved patient populations. While the Orphan Drug Act provides some [...]
By

Elisabeth Pena

Brand-cycle management
By 2005, many multibillion dollar drugs will come off patent, including blockbuster drugs such as Claritin, Viagra, Glucophage, and Prilosec (see chart on page 51). The finan cial incentives for prolonging the life of these brands are enormous. Last year, Claritin earned almost billion in sales. Viagra earned almost the same amount. In the [...]
By
PDUFA III
As time was about to expire, Congress approved legislation reauthorizing the Prescription Drug User Fee Act of 1992 (PDUFA) for five years. The reauthorization of PDUFA was included in the bioterrorism leg islation passed in May by both houses of Congress, and was signed into law by President Bush on June 11th. Without approval, PDUFA [...]
By

Kim Ribbink

Thought-Full Relationships
In the drive for market success, top companies are harnessing and capitalizing on knowledge “owned” by specialists, often referred to as thought leaders. According to Best Practices Inc., Pfizer successfully employed thoughtleader endorsements by consulting the Vatican when releasing Viagra and letting physicians review directtocon sumer advertising before launching the campaign. Thoughtleader relationship management is [...]
By
Pushing Past the Paper
PharmaVOICE W While adoption of a paperless approach by pharmaceutical companies has been gradual, Forrester Research, based on a recent survey of 400 pharmaceutical profession als, is projecting that 24% of all new clinical trials will be Web enabled by 2004. Integrated electronic applica tion, many say, is the next step in the evolutionary process. [...]
By

Taren Grom, Editor

FEEDBACK